Catalyzing innovative R&D for neglected tropical diseases, malaria, and tuberculosis
WIPO Re:Search is led by the World Intellectual Property Organization (WIPO) in partnership with BVGH and several leading pharmaceutical companies. Consortium membership includes academic and nonprofit research institutions, governmental and non-governmental organizations, and budding biotechnology companies committed to addressing the unmet medical needs of the developing world. Our 100+ Members represent 30 countries from six continents, including 25 African institutions. Download our Member list here.
The aim of the Consortium is to accelerate the development of new drugs, vaccines, and diagnostics for neglected tropical diseases, malaria, and tuberculosis. BVGH creates partnerships that connect private industry’s assets and resources to qualified academic and nonprofit researchers with novel product discovery or development ideas. Download a complete list of WIPO Re:Search partnerships here.
BVGH’s leadership is critical to the Consortium’s success. As the Partnership Hub Administrator, BVGH proactively examines scientists’ current neglected disease research and proposes novel collaboration opportunities with other Members. BVGH also fields requests from researchers, identifies Member organizations able to fulfill these requests, and helps forge mutually beneficial collaborations with clearly-defined roles, responsibilities, and expectations.
Read the most recent news in the WIPO Re:Search Snapshot.
Featured Collaboration: Eisai Co., Ltd. & Liverpool School of Tropical Medicine (LSTM)
Cerebral malaria (CM) is the most severe neurological complication of the infection by Plasmodium falciparum, resulting in seizures, coma, and death. With over 400,000 cases annually, children in sub-Saharan Africa are the most affected. Mortality is high, and around 25% of survivors develop neurological complications and cognitive impairment.
Work from Dr. Alister Craig, Dr. Chris Moxon, and colleagues at the Liverpool School of Tropical Medicine (LSTM) and University of Liverpool identified a role for protease-activated receptor (PAR) 1 in Plasmodium-mediated brain swelling. Their research demonstrated that during P. falciparum cerebral infection, PAR1 may be activated by an alternative pathway. This altered activation causes the PAR1 pathway to initiate a pro-inflammatory response, causing coagulation and inflammation – two suspected causes of brain swelling.
To assess the role of PAR1 in more detail, Dr. Craig wanted to test a selection of PAR1 inhibitors in a malaria assay that he had developed. BVGH connected Dr. Craig to vascular biology experts at Eisai Co., Ltd. (Eisai), who shared their PAR1 inhibitors. Dr. Craig has obtained encouraging results after his first round of screening the inhibitors. BVGH is currently working with Dr. Craig and the scientists at Eisai to explore different approaches to move this project forward.
To learn more about WIPO Re:Search and other collaborations, please email Ujwal Sheth at email@example.com.